< News, Press, & Events

Press Release

Genomenon Names New Commercial Leadership to Support Growth in Clinical Diagnostic and Pharmaceutical Markets

Genomenon Names New Commercial Leadership to Support Growth in Clinical Diagnostic and Pharmaceutical Markets

Company appoints Jon Murray as VP Sales, Colleen McMillen as VP Marketing, and Dave Anstey as VP Pharma Business Development

Genomenon®, Inc., a leading genomic intelligence company, has announced new executive appointments for its sales and marketing team as the company continues to expand its footprint across clinical diagnostics and pharmaceutical markets. These appointments include Jon Murray as VP Sales, Colleen McMillen as VP Marketing, and Dave Anstey as VP Pharma Business Development.

Genomenon continues to grow its business across the leading genetic testing labs and medical academic centers around the world as well as partnering with the top pharma and biopharma companies focused on genetic diseases and oncology. Earlier this year the company announced its plans to be the first to curate the human genome, further establishing its leadership role as a genomic intelligence provider. The newly appointed commercial leadership will be charged with expanding its market share, through the company’s core genomic intelligence offerings of software, data and curation and consulting services.

Previously, Murray was with Qiagen, where he was the Senior Director of Sales for all Qiagen Digital Insights products across the U.S. and Latin America, including HGMD and QDI. In this role, Murray oversaw sales teams for the clinical, pharma & biopharma markets as well as academics. Murray joined Qiagen upon the acquisition of CLCBio in 2016 and proceeded to lead more than half of QDI’s worldwide business.

Before joining Genomenon, McMillen was the VP of Communications at LumiraDx, where she oversaw all global communications initiatives for the point-of-care diagnostic company. Prior to LumiraDx, McMillen was the VP of Marketing and Communications at Celmatix Inc, driving all marketing programs for the women’s health company, including the launch of the world’s first genetic test for female reproductive health.

Anstey, who has been with Genomenon since 2018, is taking on a new role as Vice President of Pharma Business Development. In his previous role he built and led the Genomenon sales into an established genomic intelligence pioneer. He will now focus on solutions for genetic disease and cancer drug development. Prior to Genomenon, Anstey was VP Sales for Fabric Genomics.

Genomenon CEO Mike Klein stated,

“In the last year, we have continued to build and grow our relationships with the top genetic testing labs, medical academic centers and pharma companies that want to leverage our technology and tech enabled team of scientists to deliver actionable insights into the genomic drivers of genetic diseases and oncology. I am confident that with Jon, Colleen, and Dave on board we will continue this trajectory by partnering with industry leaders in their precision drug development and clinical diagnosis. We have some substantial product developments on the horizon, and the right team to solidify our leadership position as the leading genomic intelligence provider.”

Murray holds an MBA in finance from Loyola Marymount University and Bachelor of Science in biology and chemistry from California State Polytechnic University. McMillen received an MBA in marketing from NYU’s Stern School of Business and Bachelor of Journalism from the University of Missouri’s School of Journalism. Anstey holds an MBA in strategic management and International business from the University of Ottawa and Bachelor of Science in Biology Carleton University.


Genomenon is a genomics intelligence company dedicated to improving the quality of life of genetic disease and cancer patients by making genomic information actionable. Blending the power of AI with the precision of genomic expertise, the company empowers pharmaceutical companies and the clinical diagnostic community with empirical genomic evidence and insights that both support the development of novel therapeutics and speed diagnostic assessments and treatment recommendations.

Read the Article
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.